Cargando…
Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies
BACKGROUND: Short in-frame deletions in the second extracellular domain of the cytokine receptor gp130 are the leading cause of inflammatory hepatocellular adenomas (IHCAs). The deletions render gp130 constitutively active. In this study we investigate the intracellular signaling potential of one of...
Autores principales: | Rinis, Natalie, Küster, Andrea, Schmitz-Van de Leur, Hildegard, Mohr, Anne, Müller-Newen, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007646/ https://www.ncbi.nlm.nih.gov/pubmed/24612692 http://dx.doi.org/10.1186/1478-811X-12-14 |
Ejemplares similares
-
Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain
por: Mohr, Anne, et al.
Publicado: (2013) -
Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction
por: Fahrenkamp, Dirk, et al.
Publicado: (2015) -
Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization
por: Fahrenkamp, Dirk, et al.
Publicado: (2016) -
Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery
por: Görtz, Dieter, et al.
Publicado: (2015) -
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
por: Shaw, Stevan, et al.
Publicado: (2014)